Whole-body MRI with diffusion weighted sequences for Ovarian Cancer
Research type
Research Study
Full title
Evaluation of the whole-body MRI with diffusion weight sequence (WB-DWI/MRI) compared with CT for women with suspected or proven advanced ovarian cancer before or after chemotherapy on, staging and assessing operability
IRAS ID
245157
Contact name
Mahalakshmi Gurumurthy
Contact email
Sponsor organisation
NHS Grampian
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Ovarian cancer is often diagnosed at late stages with extensive peritoneal and supra diaphragmatic disease as well as metastatic disease being not uncommon at the time of first diagnosis. Complete macroscopic tumour resection has been demonstrated to be the single most important prognostic factor. If disease extent precludes upfront radical debulking surgery, neo adjuvant chemotherapy followed by interval debulking, represents a valid alternative. Imaging aims to identify patients unfit for surgery by depicting disease volume and/or extent beyond the reach of surgery (10-11). The estimate of peritoneal and particularly mesenteric and serosal bowel disease is crucial, although challenging for CT necessitating surgical staging to assess operability. Conversley, combining contrast-enhanced magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) has shown high accuracy for staging of peritoneal carcinomatosis (18/19). The aim of this study is to evaluate the diagnostic value of WB-DWI/MRI for staging and assessing operability compared with CT in patients with suspected ovarian cancer.\n\n•WB-DWI/MRI detects surgically critical metastases significantly better than CT.\n•WB-DWI/MRI particularly improves detection of serosal and distant metastases.\n•Whole body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) improves primary tumour characterisation compared to computer tomography (CT).\n\nThis is a pilot study and we aim to recruit 25 patients scheduled for surgery and suspected to have ovarian cancer. \n\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
21/NS/0022
Date of REC Opinion
26 Feb 2021
REC opinion
Favourable Opinion